Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
04 12 2020
Historique:
received: 26 10 2020
revised: 26 11 2020
accepted: 01 12 2020
entrez: 9 12 2020
pubmed: 10 12 2020
medline: 10 7 2021
Statut: epublish

Résumé

The aim of the study was to compare the prognostic significance of lymph node status of patients with lung cancer analyzed by three different methods: hematoxylin and eosin (H&E), immunohistochemistry of cytokeratin 19 (IHC CK19), and One-Step Nucleic Acid Amplification (OSNA). The clinical relevance of the results was evaluated based on relation to prognosis; the disease-free interval (DFI) and overall survival (OS) were analyzed. During radical surgical treatment, a total of 1426 lymph nodes were obtained from 100 patients, creating 472 groups of nodes (4-5 groups per patient) and examined by H&E, IHC CK19 and OSNA. The median follow-up was 44 months. Concordant results on the lymph node status of the H&E, IHC CK19 and OSNA examinations were reported in 78% of patients. We recorded shorter OS in patients with positive results provided by both OSNA and H&E. The study demonstrated a higher percentage of detected micrometastases in lymph nodes by the OSNA method. However, the higher sensitivity of the OSNA, with the cut-off value 250 copies of mRNA of CK19/µL, resulted in a lower association of OSNA positivity with progress of the disease compared to H&E. Increasing the cut-off to 615 copies resulted in an increase in concordance between the OSNA and H&E, which means that the higher cut-off is more relevant in the case of lung tumors.

Identifiants

pubmed: 33291819
pii: cells9122611
doi: 10.3390/cells9122611
pmc: PMC7762050
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Keratin-19 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Ann Thorac Cardiovasc Surg. 2014;20(3):181-4
pubmed: 23603642
Br J Cancer. 2012 May 8;106(10):1675-81
pubmed: 22531630
Ann Surg Oncol. 2014 Nov;21(12):3924-30
pubmed: 24912612
Clin Lung Cancer. 2019 May;20(3):e346-e355
pubmed: 30665872
Cancer. 2012 Dec 15;118(24):6039-45
pubmed: 22684906
Lung Cancer. 2014 Dec;86(3):318-23
pubmed: 25453845
PLoS One. 2013;8(3):e58823
pubmed: 23533593
Head Neck. 2017 Sep;39(9):1864-1868
pubmed: 28644540
Eur J Cancer. 2013 Apr;49(6):1187-95
pubmed: 23265708
Lung Cancer. 2012 Dec;78(3):212-8
pubmed: 23026640
J Surg Oncol. 2019 Mar;119(3):361-369
pubmed: 30508294
Breast. 2013 Apr;22(2):162-167
pubmed: 23375856
J Surg Oncol. 1994 Nov;57(3):139-42
pubmed: 7967601
Br J Cancer. 2014 May 13;110(10):2544-50
pubmed: 24722182
J Surg Oncol. 2018 Feb;117(2):163-170
pubmed: 29205350
PLoS One. 2017 Feb 10;12(2):e0171517
pubmed: 28187209
J Thorac Oncol. 2009 May;4(5):568-77
pubmed: 19357537
Int J Clin Oncol. 2017 Feb;22(1):3-10
pubmed: 27549784
Cells. 2020 Sep 25;9(10):
pubmed: 32992913
Hum Pathol. 2016 Feb;48:132-41
pubmed: 26614398
Eur J Surg Oncol. 2014 Feb;40(2):150-7
pubmed: 24378008
Ann Med Surg (Lond). 2019 Aug 21;46:17-22
pubmed: 31485327
J Clin Pathol. 2014 Aug;67(8):702-6
pubmed: 24906358
Lung Cancer. 2016 Jul;97:1-7
pubmed: 27237020
J Cell Physiol. 2019 Dec;234(12):21425-21435
pubmed: 31042009
Jpn J Clin Oncol. 2013 Mar;43(3):264-70
pubmed: 23293371
Int J Cancer. 2012 May 15;130(10):2377-86
pubmed: 21780107
Ann Surg Oncol. 2018 Dec;25(13):3812-3819
pubmed: 30203406

Auteurs

Josef Vodicka (J)

Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic.

Martin Pesta (M)

Department of Biology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 323 00 Plzen, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 323 00 Plzen, Czech Republic.

Vlastimil Kulda (V)

Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 301 66 Plzen, Czech Republic.

Katerina Houfkova (K)

Department of Biology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 323 00 Plzen, Czech Republic.

Bohuslava Vankova (B)

Department of Pathology, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, Edvarda Benese 13, 305 99 Plzen, Czech Republic.

Jakub Sebek (J)

Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic.

Martin Skala (M)

Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic.

Jakub Fichtl (J)

Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic.

Kristyna Prochazkova (K)

Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic.

Ondrej Topolcan (O)

Department of Immunochemistry Diagnostics, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, Edvarda Benese 13, 305 99 Plzen, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH